Medicine and Surgery
Medicine Services
Immunizations
Synagisฎ Coverage
Synagisฎ (palivizumab), a monoclonal antibody, is used to prevent lower respiratory tract diseases caused by respiratory syncytial virus in premature, high-risk infants. The treatment season for Synagisฎ is from October through April.
Providers are required to indicate CPT code 90378 (Respiratory syncytial virus immune globulin [RSV-IgIM], for intramuscular use, 50 mg, each) with the appropriate unit that indicates administered dosage (e.g., 1 unit equals 50 mg) on each claim submission. Providers may submit claims with partial quantities of Synagisฎ.
Providers should not indicate HCPCS procedure code J3490 (Unclassified drugs) when submitting claims to Wisconsin Medicaid for Synagisฎ. Claims submitted for Synagisฎ with HCPCS procedure code J3490 will be denied.
Age Restrictions
Children must be under age 24 months to begin receiving Synagisฎ. If the child turns 2 years old during the treatment season, the treatment may continue if the provider submits a completed CMS 1500 paper claim form, a request for an age restriction override, and documentation in support of the clinical need for a medical consultant review to:
Wisconsin Medicaid
Written Correspondence
6406 Bridge Rd
Madison WI 53784-0005
Next Medicine Services, Provider-Administered
Drugs
Previous Medicine Services, Immunizations, Vaccines for Recipients Older than Age 19